CoChat

Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia

Open access
Livingston, Nicholas R, Hawkins, Peter CT, Gilleen, James, Ye, Rong, Valdearenas, Lorena, Shergill, Sukhi S, Mehta, Mitul A · 2021 · Journal of Psychopharmacology

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

Background: Cognitive flexibility deficits are present in patients with schizophrenia and are strong predictors of functional outcome but, as yet, have no pharmacological treatments. Aims: The purpose of this study was to investigate whether the phosphodiesterase type-4 inhibitor, roflumilast, can improve cognitive flexibility performance and functional brain activity in patients with schizophrenia. Methods: This was a within-subject, randomised, double-blind, placebo-controlled, three-period crossover study using a version of the Intradimensional/Extradimensional (ID/ED) task, optimised for functional magnetic resonance imaging (fMRI), in 10 patients with schizophrenia who were scanned after receiving placebo, 100 µg or 250 µg roflumilast for 8 consecutive days. Data from an additional fMRI ID/ED study of 18 healthy participants on placebo was included to contextualise the schizophrenia-related performance and activations. The fMRI analyses included a priori driven region of interest (ROI) analysis of the dorsal frontoparietal attention network. Results: Patients on placebo demonstrated broad deficits in task performance compared to the healthy comparison group, accompanied by preserved network activity for solution search, but reduced activity in left ventrolateral prefrontal cortex (VLPFC) and posterior parietal cortex for attentional set-shifting and reduced activity in left dorsolateral prefrontal cortex (DLPFC) for reversal learning. These ROI deficits were ameliorated by 250 µg roflumilast, whereas during solution search 100 µg roflumilast reduced activity in the left orbitofrontal cortex, right DLPFC and bilateral PPC, which was associated with an improvement in formation of attentional sets. Conclusions: The results suggest roflumilast has dose-dependent cognitive enhancing effects on the ID/ED task in patients with schizophrenia, and provides sufficient support for larger studies to test roflumilast’s role in improving cognitive flexibility deficits in this clinical population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/02698811211000778

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Schematic example of the Hampshire and Owen Intradimensional/Extradimensional (ID/ED) task. The participant identifies the target face/building from the two compound stimuli. They are given feedback after two responses. Example: (a) In the first of the couplet, the participant chooses to follow the left building, so selects the left compound stimuli. In the second of the couplet, the stimuli are presented again, but the pairing combination is swapped. The participant now chooses the right compound stimuli, as this contains the same building. This target stimulus is incorrect and the participant receives negative feedback. (b) The participant now engages in an intradimensional (ID) shift as they shift within dimensions and choose the other building, but this is also incorrect and the participant again receives negative feedback. (c) The participant now engages in an extradimensional (ED) shift, as they shift between dimensions and choose one of the faces. This is the correct target stimulus and the participant receives positive feedback, termed ‘early correct response’. (d) and (e) The participant follows the target stimulus for another two couplets, until the participant has reached the criteria of six correct responses in a row, termed ‘late correct response’. Following this, there is a rule change which can occur in two different ways, either through a contingency change or a set change. (f) Contingency change: here, the stimuli remain the same, but the stimulus-reward contingencies are swapped, as one of the other three stimuli is now the target. Therefore, the participant must engage in a reversal learning by inhibiting their response to the previously correct stimulus (which is now incorrect) and selecting another stimulus. (g) Set change: alternatively, brand new stimuli can be introduced, whereby the participant engages in an attentional shift and begins searching for the new target stimuli.
Figure 1. Schematic example of the Hampshire and Owen Intradimensional/Extradimensional (ID/ED) task. The participant identifies the target face/building from the two compound stimuli. They are given feedback after two responses. Example: (a) In the first of the couplet, the participant chooses to follow the left building, so selects the left compound stimuli. In the second of the couplet, the stimuli are presented again, but the pairing combination is swapped. The participant now chooses the right compound stimuli, as this contains the same building. This target stimulus is incorrect and the participant receives negative feedback. (b) The participant now engages in an intradimensional (ID) shift as they shift within dimensions and choose the other building, but this is also incorrect and the participant again receives negative feedback. (c) The participant now engages in an extradimensional (ED) shift, as they shift between dimensions and choose one of the faces. This is the correct target stimulus and the participant receives positive feedback, termed ‘early correct response’. (d) and (e) The participant follows the target stimulus for another two couplets, until the participant has reached the criteria of six correct responses in a row, termed ‘late correct response’. Following this, there is a rule change which can occur in two different ways, either through a contingency change or a set change. (f) Contingency change: here, the stimuli remain the same, but the stimulus-reward contingencies are swapped, as one of the other three stimuli is now the target. Therefore, the participant must engage in a reversal learning by inhibiting their response to the previously correct stimulus (which is now incorrect) and selecting another stimulus. (g) Set change: alternatively, brand new stimuli can be introduced, whereby the participant engages in an attentional shift and begins searching for the new target stimuli.CC BY · PubMed Central
Figure 2. Visual representation of the 10 spherical regions of interest (ROIs) placed bilaterally across the dorsal frontoparietal attention network as taken from Hampshire and Owen (2006). From left to right, this includes the lateral orbitofrontal cortex (green), ventrolateral prefrontal cortex (yellow), dorsolateral prefrontal cortex (red), medial orbitofrontal cortex (blue) and posterior parietal cortex (pink).
Figure 2. Visual representation of the 10 spherical regions of interest (ROIs) placed bilaterally across the dorsal frontoparietal attention network as taken from Hampshire and Owen (2006). From left to right, this includes the lateral orbitofrontal cortex (green), ventrolateral prefrontal cortex (yellow), dorsolateral prefrontal cortex (red), medial orbitofrontal cortex (blue) and posterior parietal cortex (pink).CC BY · PubMed Central
Figure 3. Behavioural and imaging results for the healthy comparison group and patients with schizophrenia on placebo: (a) bar chart showing mean number of errors made according to category type of dimensional shift (intradimensional (ID) and extradimensional (ED)) and target change (set change and contingency change); (b) bar chart showing beta values extracted from the 10 regions of interest (ROIs) for the searching > known contrast; (c) bar chart showing beta values extracted from the 10 ROIs for the ED shift > ID shift contrast; (d) bar chart showing beta values extracted from the 10 ROIs for the contingency change > set change contrast. Error bars represent standard error of the mean (SEM) and * denotes p < 0.05 after correction for multiple comparisons (see text for details). * Above a column (panel (b), (c) and (d)) denotes a change in contrast, whilst a * above connecting lines (panel (a), (c) and (d)) denotes a difference between groups or conditions. DLPFC: dorsolateral prefrontal cortex; L: left; lOFC: lateral orbitofrontal cortex; mOFC: medial orbitofrontal cortex; PPC: posterior parietal cortex; R: right; VLPFC: ventrolateral prefrontal cortex.
Figure 3. Behavioural and imaging results for the healthy comparison group and patients with schizophrenia on placebo: (a) bar chart showing mean number of errors made according to category type of dimensional shift (intradimensional (ID) and extradimensional (ED)) and target change (set change and contingency change); (b) bar chart showing beta values extracted from the 10 regions of interest (ROIs) for the searching > known contrast; (c) bar chart showing beta values extracted from the 10 ROIs for the ED shift > ID shift contrast; (d) bar chart showing beta values extracted from the 10 ROIs for the contingency change > set change contrast. Error bars represent standard error of the mean (SEM) and * denotes p < 0.05 after correction for multiple comparisons (see text for details). * Above a column (panel (b), (c) and (d)) denotes a change in contrast, whilst a * above connecting lines (panel (a), (c) and (d)) denotes a difference between groups or conditions. DLPFC: dorsolateral prefrontal cortex; L: left; lOFC: lateral orbitofrontal cortex; mOFC: medial orbitofrontal cortex; PPC: posterior parietal cortex; R: right; VLPFC: ventrolateral prefrontal cortex.CC BY · PubMed Central
Figure 4. Behavioural and imaging results for the healthy comparison group and patients with schizophrenia on placebo, 100 μg and 250 μg roflumilast: (a) bar chart showing mean number of errors made whilst searching for the target according to category type of dimensional shift (intradimensional (ID) and extradimensional (ED)) and target change (set change and contingency change); (b) bar chart showing beta values extracted from the 10 regions of interest (ROIs) for the searching > known contrast; (c) bar chart showing beta values extracted from the 10 ROIs for the ED shift > ID shift contrast; (d) bar chart showing beta values extracted from the 10 ROIs for the contingency change > set change contrast. Error bars represent standard error of the mean (SEM) and * denotes p < 0.05 after corrections for multiple comparisons. * Above a column (panel (b), (c) and (d)) denotes a change in contrast, whilst a * above connecting lines (panel (a), (c) and (d)) denotes a difference between groups or conditions, and ‘ns’ denotes ‘no significance’. DLPFC: dorsolateral prefrontal cortex; L: left; lOFC: lateral orbitofrontal cortex; mOFC: medial orbitofrontal cortex; PPC: posterior parietal cortex; R: right; VLPFC: ventrolateral prefrontal cortex.
Figure 4. Behavioural and imaging results for the healthy comparison group and patients with schizophrenia on placebo, 100 μg and 250 μg roflumilast: (a) bar chart showing mean number of errors made whilst searching for the target according to category type of dimensional shift (intradimensional (ID) and extradimensional (ED)) and target change (set change and contingency change); (b) bar chart showing beta values extracted from the 10 regions of interest (ROIs) for the searching > known contrast; (c) bar chart showing beta values extracted from the 10 ROIs for the ED shift > ID shift contrast; (d) bar chart showing beta values extracted from the 10 ROIs for the contingency change > set change contrast. Error bars represent standard error of the mean (SEM) and * denotes p < 0.05 after corrections for multiple comparisons. * Above a column (panel (b), (c) and (d)) denotes a change in contrast, whilst a * above connecting lines (panel (a), (c) and (d)) denotes a difference between groups or conditions, and ‘ns’ denotes ‘no significance’. DLPFC: dorsolateral prefrontal cortex; L: left; lOFC: lateral orbitofrontal cortex; mOFC: medial orbitofrontal cortex; PPC: posterior parietal cortex; R: right; VLPFC: ventrolateral prefrontal cortex.CC BY · PubMed Central
Figure 5. Scatter plot showing a correlation between reduction in average number of errors per trial and reduction in averaged network activity for 100 μg roflumilast compared to placebo.
Figure 5. Scatter plot showing a correlation between reduction in average number of errors per trial and reduction in averaged network activity for 100 μg roflumilast compared to placebo.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 3

  1. Brett M, 2002, Neuroimage, 13, 210
  2. Elvevag B, 2012, Crit Rev Neurobiol, 14, 1
  3. Roberts AC, 1988, Q J Exp Psychol B, 40, 321

Cited by

See all 17

Metadata

Authors
Livingston, N. R., Hawkins, P. C., Gilleen, J., Ye, R., Valdearenas, L., Shergill, S. S., & Mehta, M. A.
Affiliations
  • King's College London (GB)
  • University of Cambridge (GB)
  • Barnet Enfield and Haringey Mental Health Trust (GB)
  • Department of Psychosis Studies, King’s College London, London, UK
Corresponding author
Mehta, Mitul A
Venue
Journal of Psychopharmacology
Published
2021-04-28
Volume
35
Issue
9
Pages
1099-1110
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W3157931311
Cited by
17
References
69
Citations by year
2026: 4 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 4 · 2021: 1
FWCI
1.79
Type
journal article
Language
en
Open access
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Kent Academic Repository (University of Kent) (submittedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
Takeda Pharmaceutical Company (ROF-SCHZ_106)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
roflumilast, phosphodiesterase-4 inhibitors, schizophrenia, cognitive flexibility, set-shifting, reversal learning, solution search, ventrolateral prefrontal cortex, dorsolateral prefrontal cortex, posterior parietal cortex, orbitofrontal cortex, functional brain activity, cognitive enhancement
MeSH terms
Dorsolateral Prefrontal Cortex, Adult, Aged, Aminopyridines, Benzamides, Cyclopropanes, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neuropsychological Tests, Schizophrenia, Prefrontal Cortex, Cross-Over Studies, Phosphodiesterase 4 Inhibitors, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia. https://app.cochat.ai/papers/10.1177/02698811211000778
The paper
Livingston, N. R., Hawkins, P. C., Gilleen, J., Ye, R., Valdearenas, L., Shergill, S. S., & Mehta, M. A. (2021). Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia. Journal of Psychopharmacology. https://doi.org/10.1177/02698811211000778

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.